Leptin therapy in insulin-deficient type I diabetes

May-Yun Wang, Lijun Chen, Gregory O. Clark, Young H Lee, Robert D. Stevens, Olga R. Ilkayeva, Brett R. Wenner, James R. Bain, Maureen J. Charron, Christopher B. Newgard, Roger H Unger

Research output: Contribution to journalArticle

220 Citations (Scopus)

Abstract

In nonobese diabetic mice with uncontrolled type 1 diabetes, leptin therapy alone or combined with low-dose insulin reverses the catabolic state through suppression of hyperglucagonemia. Additionally, it mimics the anabolic actions of insulin monotherapy and normalizes hemoglobin A1c with far less glucose variability. We showthat leptin therapy, like insulin, normalizes the levels of a wide array of hepatic intermediary metabolites in multiple chemical classes, including acylcarnitines, organic acids (tricarboxylic acid cycle intermediates), amino acids, and acyl CoAs. In contrast to insulin monotherapy, however, leptin lowers both lipogenic and cholesterologenic transcription factors and enzymes and reduces plasma and tissue lipids. The results imply that leptin administration may have multiple short- and long-term advantages over insulin monotherapy for type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)4813-4819
Number of pages7
JournalProceedings of the National Academy of Sciences of the United States of America
Volume107
Issue number11
DOIs
StatePublished - Mar 16 2010

Fingerprint

Leptin
Type 1 Diabetes Mellitus
Insulin
Therapeutics
Inbred NOD Mouse
Citric Acid Cycle
Hemoglobins
Transcription Factors
Lipids
Amino Acids
Glucose
Acids
Liver
Enzymes

Keywords

  • Cholesterol regulation
  • Glucagon suppression
  • Glucose regulation
  • Lipid-lowering
  • Metabolomics

ASJC Scopus subject areas

  • General

Cite this

Leptin therapy in insulin-deficient type I diabetes. / Wang, May-Yun; Chen, Lijun; Clark, Gregory O.; Lee, Young H; Stevens, Robert D.; Ilkayeva, Olga R.; Wenner, Brett R.; Bain, James R.; Charron, Maureen J.; Newgard, Christopher B.; Unger, Roger H.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 11, 16.03.2010, p. 4813-4819.

Research output: Contribution to journalArticle

Wang, M-Y, Chen, L, Clark, GO, Lee, YH, Stevens, RD, Ilkayeva, OR, Wenner, BR, Bain, JR, Charron, MJ, Newgard, CB & Unger, RH 2010, 'Leptin therapy in insulin-deficient type I diabetes', Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 11, pp. 4813-4819. https://doi.org/10.1073/pnas.0909422107
Wang, May-Yun ; Chen, Lijun ; Clark, Gregory O. ; Lee, Young H ; Stevens, Robert D. ; Ilkayeva, Olga R. ; Wenner, Brett R. ; Bain, James R. ; Charron, Maureen J. ; Newgard, Christopher B. ; Unger, Roger H. / Leptin therapy in insulin-deficient type I diabetes. In: Proceedings of the National Academy of Sciences of the United States of America. 2010 ; Vol. 107, No. 11. pp. 4813-4819.
@article{985a6452facb4a74a3082c78790fb3b0,
title = "Leptin therapy in insulin-deficient type I diabetes",
abstract = "In nonobese diabetic mice with uncontrolled type 1 diabetes, leptin therapy alone or combined with low-dose insulin reverses the catabolic state through suppression of hyperglucagonemia. Additionally, it mimics the anabolic actions of insulin monotherapy and normalizes hemoglobin A1c with far less glucose variability. We showthat leptin therapy, like insulin, normalizes the levels of a wide array of hepatic intermediary metabolites in multiple chemical classes, including acylcarnitines, organic acids (tricarboxylic acid cycle intermediates), amino acids, and acyl CoAs. In contrast to insulin monotherapy, however, leptin lowers both lipogenic and cholesterologenic transcription factors and enzymes and reduces plasma and tissue lipids. The results imply that leptin administration may have multiple short- and long-term advantages over insulin monotherapy for type 1 diabetes.",
keywords = "Cholesterol regulation, Glucagon suppression, Glucose regulation, Lipid-lowering, Metabolomics",
author = "May-Yun Wang and Lijun Chen and Clark, {Gregory O.} and Lee, {Young H} and Stevens, {Robert D.} and Ilkayeva, {Olga R.} and Wenner, {Brett R.} and Bain, {James R.} and Charron, {Maureen J.} and Newgard, {Christopher B.} and Unger, {Roger H}",
year = "2010",
month = "3",
day = "16",
doi = "10.1073/pnas.0909422107",
language = "English (US)",
volume = "107",
pages = "4813--4819",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "11",

}

TY - JOUR

T1 - Leptin therapy in insulin-deficient type I diabetes

AU - Wang, May-Yun

AU - Chen, Lijun

AU - Clark, Gregory O.

AU - Lee, Young H

AU - Stevens, Robert D.

AU - Ilkayeva, Olga R.

AU - Wenner, Brett R.

AU - Bain, James R.

AU - Charron, Maureen J.

AU - Newgard, Christopher B.

AU - Unger, Roger H

PY - 2010/3/16

Y1 - 2010/3/16

N2 - In nonobese diabetic mice with uncontrolled type 1 diabetes, leptin therapy alone or combined with low-dose insulin reverses the catabolic state through suppression of hyperglucagonemia. Additionally, it mimics the anabolic actions of insulin monotherapy and normalizes hemoglobin A1c with far less glucose variability. We showthat leptin therapy, like insulin, normalizes the levels of a wide array of hepatic intermediary metabolites in multiple chemical classes, including acylcarnitines, organic acids (tricarboxylic acid cycle intermediates), amino acids, and acyl CoAs. In contrast to insulin monotherapy, however, leptin lowers both lipogenic and cholesterologenic transcription factors and enzymes and reduces plasma and tissue lipids. The results imply that leptin administration may have multiple short- and long-term advantages over insulin monotherapy for type 1 diabetes.

AB - In nonobese diabetic mice with uncontrolled type 1 diabetes, leptin therapy alone or combined with low-dose insulin reverses the catabolic state through suppression of hyperglucagonemia. Additionally, it mimics the anabolic actions of insulin monotherapy and normalizes hemoglobin A1c with far less glucose variability. We showthat leptin therapy, like insulin, normalizes the levels of a wide array of hepatic intermediary metabolites in multiple chemical classes, including acylcarnitines, organic acids (tricarboxylic acid cycle intermediates), amino acids, and acyl CoAs. In contrast to insulin monotherapy, however, leptin lowers both lipogenic and cholesterologenic transcription factors and enzymes and reduces plasma and tissue lipids. The results imply that leptin administration may have multiple short- and long-term advantages over insulin monotherapy for type 1 diabetes.

KW - Cholesterol regulation

KW - Glucagon suppression

KW - Glucose regulation

KW - Lipid-lowering

KW - Metabolomics

UR - http://www.scopus.com/inward/record.url?scp=77950373635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950373635&partnerID=8YFLogxK

U2 - 10.1073/pnas.0909422107

DO - 10.1073/pnas.0909422107

M3 - Article

C2 - 20194735

AN - SCOPUS:77950373635

VL - 107

SP - 4813

EP - 4819

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 11

ER -